Osman Melih Topcuoğlu, Türkay Toklu, Nalan Alan Selçuk, Betül Uzunoğlu
{"title":"Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases.","authors":"Osman Melih Topcuoğlu, Türkay Toklu, Nalan Alan Selçuk, Betül Uzunoğlu","doi":"10.1016/j.jvir.2025.08.045","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (<sup>90</sup>Y) transarterial radioembolization (TARE).</p><p><strong>Materials and methods: </strong>Between August 2016 and August 2024, patients with BCLM who underwent <sup>90</sup>Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression-free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.</p><p><strong>Results: </strong>Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3-9.0 months) and 4.2 months (IQR, 2.5-5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (P = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5-14.8 months) and 4.1 months (IQR, 3.1-6.3 months) versus 4.0 months (IQR, 2.5-4.5 months) and 2.1 months (IQR, 1.3-2.7 months), respectively (P = .025 and P = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (P = .024 and P = .397, respectively).</p><p><strong>Conclusions: </strong>Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vascular and Interventional Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jvir.2025.08.045","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (90Y) transarterial radioembolization (TARE).
Materials and methods: Between August 2016 and August 2024, patients with BCLM who underwent 90Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression-free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.
Results: Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3-9.0 months) and 4.2 months (IQR, 2.5-5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (P = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5-14.8 months) and 4.1 months (IQR, 3.1-6.3 months) versus 4.0 months (IQR, 2.5-4.5 months) and 2.1 months (IQR, 1.3-2.7 months), respectively (P = .025 and P = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (P = .024 and P = .397, respectively).
Conclusions: Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.
期刊介绍:
JVIR, published continuously since 1990, is an international, monthly peer-reviewed interventional radiology journal. As the official journal of the Society of Interventional Radiology, JVIR is the peer-reviewed journal of choice for interventional radiologists, radiologists, cardiologists, vascular surgeons, neurosurgeons, and other clinicians who seek current and reliable information on every aspect of vascular and interventional radiology. Each issue of JVIR covers critical and cutting-edge medical minimally invasive, clinical, basic research, radiological, pathological, and socioeconomic issues of importance to the field.